Literature DB >> 16800850

The neuronal excitatory amino acid transporter EAAC1/EAAT3: does it represent a major actor at the brain excitatory synapse?

André Nieoullon1, Benoit Canolle, Frédérique Masmejean, Benjamin Guillet, Pascale Pisano, Sylviane Lortet.   

Abstract

EAAC1/EAAT3 is a transporter of glutamate (Glu) present at the post-synaptic neuronal element, in opposition to the two other main transporters, GLAST/EAAT1 and GLT1/EAAT2, expressed at the excitatory amino acid (EAA) synapse by surrounding astrocytes. Although, in the adult, EAAC1/EAAT3 exhibits a rather low expression level and is considered to make a minor contribution to Glu removal from the synapse, its early expression during brain development, before the astrocytes are functional, suggests that such a neuronal transporter is involved in the developmental effects of EAA and, possibly, in the biosynthesis and trophic role of GABA, which is excitatory in nature in different brain regions during the earlier stages of brain development. This neuronal Glu transporter is considered to have a dual action as it is apparently involved in the neuronal uptake of cysteine, which acts as a key substrate for the synthesis of glutathione, a major anti-oxidant, because the neurones do not express the Xc(-) transport system in the mature brain. Interestingly, EAAC1/EAAT3 activity/expression was shown to be highly regulated by neuronal activity as well as by intracellular signalling pathways involving primarily alpha protein kinase C (alphaPKC) and phosphatidylinositol-3-kinase (PI3K). Such regulatory processes could act either at the post-traductional level or at the transcriptional level. It is worth noting that EAAC1/EAAT3 exhibits specificity, compared with other EAA transporters, because it is present mainly in the intracellular compartment and only for about 20% at the plasma membrane. Variations in neuronal Glu uptake were shown to be associated with rapid changes in the trafficking of the transporter protein altering the membranar location of the transporter. More recent data show that astrocyte-secreted factors such as cholesterol could also influence rapid changes in the location of EAAC1/EAAT3 between the plasma membrane and the cytoplasmic compartment. Such a highly regulated process of EAAC1/EAAT3 activity/expression may have implications in the physiopathology of major diseases affecting EAA brain signalling, which is further supported by data obtained in animal models of hypoxia-anoxia, for example.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16800850     DOI: 10.1111/j.1471-4159.2006.03978.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  55 in total

1.  mRNA for the EAAC1 subtype of glutamate transporter is present in neuronal dendrites in vitro and dramatically increases in vivo after a seizure.

Authors:  John R Ross; Brenda E Porter; Peter T Buckley; James H Eberwine; Michael B Robinson
Journal:  Neurochem Int       Date:  2010-12-24       Impact factor: 3.921

2.  Aberrant Rab11-dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington's disease.

Authors:  Xueyi Li; Antonio Valencia; Ellen Sapp; Nicholas Masso; Jonathan Alexander; Patrick Reeves; Kimberly B Kegel; Neil Aronin; Marian Difiglia
Journal:  J Neurosci       Date:  2010-03-31       Impact factor: 6.167

3.  Morphine induces redox-based changes in global DNA methylation and retrotransposon transcription by inhibition of excitatory amino acid transporter type 3-mediated cysteine uptake.

Authors:  Malav Trivedi; Jayni Shah; Nathaniel Hodgson; Hyang-Min Byun; Richard Deth
Journal:  Mol Pharmacol       Date:  2014-02-25       Impact factor: 4.436

4.  OCD candidate gene SLC1A1/EAAT3 impacts basal ganglia-mediated activity and stereotypic behavior.

Authors:  Isaac D Zike; Muhammad O Chohan; Jared M Kopelman; Emily N Krasnow; Daniel Flicker; Katherine M Nautiyal; Michael Bubser; Christoph Kellendonk; Carrie K Jones; Gregg Stanwood; Kenji Fransis Tanaka; Holly Moore; Susanne E Ahmari; Jeremy Veenstra-VanderWeele
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-15       Impact factor: 11.205

Review 5.  The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies.

Authors:  Wei Hu; Matthew L MacDonald; Daniel E Elswick; Robert A Sweet
Journal:  Ann N Y Acad Sci       Date:  2014-10-14       Impact factor: 5.691

Review 6.  Rodent models of obsessive compulsive disorder: Evaluating validity to interpret emerging neurobiology.

Authors:  Isaac Zike; Tim Xu; Natalie Hong; Jeremy Veenstra-VanderWeele
Journal:  Neuroscience       Date:  2016-09-16       Impact factor: 3.590

7.  Characterization of a Novel Mutation in SLC1A1 Associated with Schizophrenia.

Authors:  Parisa Afshari; Marina Myles-Worsley; Ori S Cohen; Josepha Tiobech; Stephen V Faraone; William Byerley; Frank A Middleton
Journal:  Mol Neuropsychiatry       Date:  2015-07-08

Review 8.  Brain imaging in pediatric obsessive-compulsive disorder.

Authors:  Frank P MacMaster; Joseph O'Neill; David R Rosenberg
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-11       Impact factor: 8.829

9.  Cortical metabolism in pyruvate dehydrogenase deficiency revealed by ex vivo multiplet (13)C NMR of the adult mouse brain.

Authors:  Isaac Marin-Valencia; Levi B Good; Qian Ma; Craig R Malloy; Mulchand S Patel; Juan M Pascual
Journal:  Neurochem Int       Date:  2012-08-03       Impact factor: 3.921

10.  Involvement of glutamatergic neurotransmission in the antidepressant-like effect of zinc in the chronic unpredictable stress model of depression.

Authors:  Luana M Manosso; Morgana Moretti; André R Colla; Camille M Ribeiro; Tharine Dal-Cim; Carla I Tasca; Ana Lúcia S Rodrigues
Journal:  J Neural Transm (Vienna)       Date:  2016-01-08       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.